選択的DRD2拮抗薬ONC201で治療された小児および成人のH3 K27M変異体びまん性正中神経膠腫 https://t.co/4j0I2C4CDN
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201 https://t.co/nJMfbagZe4 #readlater #feedly
This is freaking amazing 😱 We are so close to a cure, man. 😩
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @laura1127md: Please, please, please work! Early results seem promising. #DIPG #midlineglioma #H3K27M #glioma #GBM #childrenscanceraware…
RT @laura1127md: Please, please, please work! Early results seem promising. #DIPG #midlineglioma #H3K27M #glioma #GBM #childrenscanceraware…
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
RT @laura1127md: Please, please, please work! Early results seem promising. #DIPG #midlineglioma #H3K27M #glioma #GBM #childrenscanceraware…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
Please, please, please work! Early results seem promising. #DIPG #midlineglioma #H3K27M #glioma #GBM #childrenscancerawarenessmonth #research
RT @L8Effects: RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks.“ Progress against #DIPG cannot come soon enough🎗 #Childhood… http
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @leezawilllshe: RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks.“ Progress against #DIPG cannot come soon enough🎗 #Child… http
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progressio…
RT @HappyQuailPress: “Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks.“ Progress against #DIPG cannot come soon enough🎗 #ChildhoodCancer #KickCh… http
“Among the 4 pediatric patients who initiated adjuvant ONC201 following radiation, two DIPG patients remain progression-free for at least 53 and 81 weeks.“ Progress against #DIPG cannot come soon enough🎗 #ChildhoodCancer #KickChildhoodCancer
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
Really excited to see that our lead molecule, ONC201 doing something meaningful in patients with this dreaded form high grade glioma.
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
RT @AshleySumrallMD: Check out our data on #ONC201 in recurrent #H3K27m mutated glioma! #btsm @JNeurooncol https://t.co/YQtPgQO9WK
RT @JNeurooncol: Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #n…
Preliminary results support clinical testing of the DRD2 antagonist, ONC201 for H3-K27M-mutant diffuse midline gliomas. #nsgy https://t.co/Ehc05Oywsp https://t.co/NSNTSbT4RE
RT @YoshieUmemura: so glad my patient in this @JNeurooncol article https://t.co/kABOtujClZ is still having reduction in size of her #braint…
RT @YoshieUmemura: so glad my patient in this @JNeurooncol article https://t.co/kABOtujClZ is still having reduction in size of her #braint…
Check out our data on #ONC201 in recurrent #H3K27m mutated glioma! #btsm @JNeurooncol https://t.co/YQtPgQO9WK
so glad my patient in this @JNeurooncol article https://t.co/kABOtujClZ is still having reduction in size of her #braintumor on #expandedaccess #ONC201 💊 monotherapy! fingers crossed for a durable response 🤞 @UMRogelCancer @UMneurosciences @umichmedicine @